The Billion-Dollar Molecule (Record no. 4424)
[ view plain ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 01561nam a2200241Ia 4500 |
| 003 - CONTROL NUMBER IDENTIFIER | |
| control field | ASM |
| 005 - DATE AND TIME OF LATEST TRANSACTION | |
| control field | 20241206092907.0 |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION | |
| fixed length control field | 241203s9999 xx 000 0 und d |
| 020 ## - INTERNATIONAL STANDARD BOOK NUMBER | |
| International Standard Book Number | 0671510576 |
| 020 ## - INTERNATIONAL STANDARD BOOK NUMBER | |
| International Standard Book Number | 9780671510572 |
| 020 ## - INTERNATIONAL STANDARD BOOK NUMBER | |
| Qualifying information | Paperback |
| 040 ## - CATALOGING SOURCE | |
| Transcribing agency | ASM |
| 050 ## - LIBRARY OF CONGRESS CALL NUMBER | |
| Classification number | |
| 100 ## - MAIN ENTRY--PERSONAL NAME | |
| Personal name | Barry Werth |
| Relator term | Author |
| 110 ## - MAIN ENTRY--CORPORATE NAME | |
| Corporate name or jurisdiction name as entry element | Barry Werth |
| 245 #4 - TITLE STATEMENT | |
| Title | The Billion-Dollar Molecule |
| Remainder of title | One Company's Quest for the Perfect Drug |
| Statement of responsibility, etc. | Barry Werth |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. | |
| Place of publication, distribution, etc. | United States of America |
| Name of publisher, distributor, etc. | Simon & Schuster |
| Date of publication, distribution, etc. | 1994 |
| 300 ## - PHYSICAL DESCRIPTION | |
| Extent | 455 pages |
| Other physical details | illustrations |
| Dimensions | 22 cm |
| 520 ## - SUMMARY, ETC. | |
| Summary, etc. | "Join journalist Barry Werth as he pulls back the curtain on Vertex, a start-up pharmaceutical company, and witness firsthand the intense drama being played out in the pioneering and hugely profitable field of drug research. Founded by Joshua Boger, a dynamic Harvard- and Merck-trained scientific whiz kid, Vertex is dedicated to designing -- atom by atom -- both a new life-saving immunosuppressant drug, and a drug to combat the virus that causes AIDS. You will be hooked from start to finish, as you go from the labs, where obsessive, fiercely competitive scientists struggle for a breakthrough, to Wall Street, where the wheeling and dealing takes on a life of its own, as Boger courts investors and finally decides to take Vertex public. Here is a fascinating no-holds-barred account of the business of science, which includes an updated epilogue about the most recent developments in the quest for a drug to cure AIDS." |
| 546 ## - LANGUAGE NOTE | |
| Language note | English |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Medicine |
| 942 ## - ADDED ENTRY ELEMENTS (KOHA) | |
| Koha item type | |
No items available.